Virios Therapeutics, Inc., a development-stage biotechnology company, focuses on developing antiviral therapies to treat diseases associated with a viral triggered abnormal immune response. The company's lead development candidate is the IMC-1, a fixed dose combination of famciclovir and celecoxib to treat fibromyalgia. It is also developing IMC-2, a combination of valacyclovir and celecoxib for the treatment of managing the fatigue, sleep, attention, pain, autonomic function, and anxiety associated with long COVID. The company was formerly known as Virios Therapeutics, LLC and changed its name to Virios Therapeutics, Inc. in December 2020. Virios Therapeutics, Inc. was founded in 2012 and is headquartered in Alpharetta, Georgia.

Filer	Shares	Latest Filing Date	Previously owned	Change	Share-Type	Market Value
Masters Capital Management Llc	447.96K	2021-02-16	0	447.96K	Shares	3.36M
Jane Street Group, Llc	95.23K	2021-02-17	0	95.23K	Shares	715K
Virtu Financial Llc	35.22K	2021-02-24	0	35.22K	Shares	264K
Millennium Management Llc	20.70K	2021-02-16	0	20.70K	Shares	155K
Ubs Group Ag	3.32K	2021-02-11	0	3.32K	Shares	25K
Morgan Stanley	1.44K	2021-02-16	0	1.44K	Shares	11K
Fny Investment Advisers, Llc	1K	2021-01-19	0	1K	Shares	7K
Pathstone Family Office, Llc	500	2021-02-16	0	500	Shares	4K
Advisor Group Holdings, Inc.	418	2021-02-10	0	418	Shares	3K
Pvg Asset Management Corp	0	2023-07-31	80.59K	-80.59K	Shares	0
Concourse Financial Group S...	0	2021-02-02	0	0	Shares	0

NASDAQ:VIRI

Virios Therapeutics, Inc.

Last Close

0.42

03/05 20:00

Market Cap

7.90M

Beta: 1.93

Volume Today

67.34K

Avg: 2.87M

PE Ratio

−1.08

PFCF: −1.11

Institutional trades

Institutional Ownership

Current holdings institutionals